BTIG Thinks Delcath Systems’ Stock is Going to Recover

BTIG analyst Marie Thibault reiterated a Buy rating on Delcath Systems (DCTHResearch Report) today and set a price target of $23.00. The company’s shares closed last Monday at $4.50, close to its 52-week low of $4.25.

According to, Thibault is a 4-star analyst with an average return of 9.0% and a 29.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Delcath Systems with a $21.33 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Delcath Systems’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $378K and GAAP net loss of $8.2 million. In comparison, last year the company earned revenue of $388K and had a GAAP net loss of $6.75 million.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DCTH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.

Read More on DCTH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More